CA19-9 and response to chemotherapy in cancer of the pancreas
1998

CA19-9 and Response to Chemotherapy in Pancreatic Cancer

Sample size: 39 publication Evidence: moderate

Author Information

Author(s): H Gogas, FJ Lofts, TRJ Evans, S Daryanani, JL Mansi

Primary Institution: Department of Oncology, St George's Hospital, London, UK

Hypothesis

Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

Conclusion

CA19-9 may be of limited use as the primary means of follow-up, but a reduction in CA19-9 levels can indicate a better survival outcome.

Supporting Evidence

  • 35 of 39 patients had elevated CA19-9 levels.
  • 13 patients exhibited a decrease in CA19-9 levels during treatment.
  • The median survival for patients with a reduction in CA19-9 was 333 days.
  • The sensitivity of CA19-9 for predicting a partial response was 67%.
  • The difference in median survival between patients with a decrease and those with an increase in CA19-9 was significant.

Takeaway

Doctors measured a substance called CA19-9 in patients with pancreatic cancer to see if it could help predict how well their treatment was working. If the levels went down, it usually meant the patients were doing better.

Methodology

Patients received chemotherapy and had their CA19-9 levels measured at baseline and before each cycle, with changes compared to CT scans.

Limitations

The positive predictive value of CA19-9 was not high enough to rely on it alone for assessing treatment response.

Participant Demographics

39 patients (27 male, 12 female; median age 60 years, range 39-75 years) with inoperable pancreatic adenocarcinoma.

Statistical Information

P-Value

0.001

Statistical Significance

p=0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication